KALA Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

-0.320

-81.61%

-0.170

-87.94%

-0.120

-92.98%

Estimates Revision

The market is revising No Change the revenue expectations for KALA BIO, Inc. (KALA) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -58.13%.

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Down

-58.13%

In Past 3 Month

2 Analyst Rating

Wall Street analysts forecast KALA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KALA is 1.50 USD with a low forecast of 1.50 USD and a high forecast of 1.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

0 Buy

2 Hold

0 Sell

Hold

Current: 0.000

Low

1.50

Averages

1.50

High

1.50

Current: 0.000

Low

1.50

Averages

1.50

High

1.50

Morgan Stanley

Overweight

maintain

$28 -> $30

2026-01-08

New

Reason

Morgan Stanley

Price Target

$28 -> $30

2026-01-08

New

maintain

Overweight

Reason

Morgan Stanley raised the firm's price target on Cullinan Therapeutics to $30 from $28 and keeps an Overweight rating on the shares. The firm sees a continuation of U.S. small-to-mid cap biotech's outperformance in 2026 as commercial names transition from "capital consumers to producers" and Large Cap Biopharma faces a looming patent cliff, the analyst tells investors in an outlook note for the group.

H.C. Wainwright

Buy

maintain

$26 -> $27

2026-01-08

New

Reason

H.C. Wainwright

Price Target

$26 -> $27

2026-01-08

New

maintain

Buy

Reason

H.C. Wainwright raised the firm's price target on Cullinan Therapeutics to $27 from $26 and keeps a Buy rating on the shares after the company announced its 2026 milestones.

Clear Street

Buy

maintain

$22 -> $33

2025-12-09

Reason

Clear Street

Price Target

$22 -> $33

2025-12-09

maintain

Buy

Reason

Clear Street raised the firm's price target on Cullinan Therapeutics to $33 from $22 and keeps a Buy rating on the shares after the company announced updated data from the Phase 1 study of CLN-049. CLN-049's clinical data appear superior to most CD3 bispecifics, which reinforces its "differentiated biology and therapeutic potential," the analyst tells investors in a research note. Clear Street introduced an acute myeloid leukemia market model for CLN-049 with a 2028 launch and project risk-adjusted peak sales of $500M in 2040.

Mizuho

Outperform

Neutral

downgrade

$30

2025-09-30

Reason

Mizuho

Price Target

$30

2025-09-30

downgrade

Outperform

Neutral

Reason

Mizuho downgraded Kala Bio to Neutral from Outperform with a price target of $1.50, down from $30. The firm cites yesterday's negative Phase 2 results for the company's lead asset KPI-012 for the downgrade. Mizuho is \"very disappointed\" by the data and has been unable to connect with management. The analyst removed KPI-012 Kala's model and downgraded the shares.

LifeSci Capital

Outperform -> Market Perform

downgrade

2025-09-29

Reason

LifeSci Capital

Price Target

2025-09-29

downgrade

Outperform -> Market Perform

Reason

LifeSci Capital downgraded Kala Pharmaceuticals to Market Perform from Outperform and removed the firm's price target after the company announced that its CHASE Phase 2b clinical trial of KPI-012 for the treatment of persistent corneal epithelial defect did not meet its primary endpoint and that the company plans to cease development of KPI-012 and its mesenchymal stem cell secretome platform based on the CHASE trial results.

Mizuho

Graig Suvannavejh

downgrade

2025-09-29

Reason

Mizuho

Graig Suvannavejh

Price Target

2025-09-29

downgrade

Reason

Mizuho analyst Graig Suvannavejh expects \"material weakness\" in Kala Pharmaceuticals shares today after the company announced that KPI-012 failed to achieve all primary and secondary end points in its Phase 2a study in persistent corneal epithelial defect. Kala shares shared no data details and is not hosting a call which is disappointing, the analyst tells investors in a research note. The stock in morning trading is down 90%, or $17.14, to $1.91.

Valuation Metrics

The current forward P/E ratio for KALA BIO Inc (KALA.O) is -0.85, compared to its 5-year average forward P/E of -1.45. For a more detailed relative valuation and DCF analysis to assess KALA BIO Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-1.45

Current PE

-0.85

Overvalued PE

-0.29

Undervalued PE

-2.60

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-0.51

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.73

Undervalued EV/EBITDA

-1.76

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

5.17

Current PS

0.00

Overvalued PS

14.46

Undervalued PS

-4.13

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders areSelling! The selling amount has increased 177.3% over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders areSelling! The selling amount has increased 177.3% over the last month.

Sold

Bought

KALA News & Events

Events Timeline

No data

News

2.0

01-06NASDAQ.COM

KALA BIO Settles $10.6 Million Loan with Oxford Finance, Enhancing Financial Flexibility

7.5

01-06Benzinga

Cyclerion Therapeutics Expands Collaboration with Medsteer, Shares Surge 44.2%

4.5

01-05Yahoo Finance

Kala Bio (KALA) Completes $10.6 Million Loan Settlement

People Also Watch

Frequently Asked Questions

What is KALA BIO Inc (KALA) stock price today?

The current price of KALA is 0.649 USD — it has decreased -2.41 % in the last trading day.

What is KALA BIO Inc (KALA)'s business?

KALA BIO, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the research, development, and commercialization of therapies for rare and severe diseases of the eye. The Company’s biologics-based investigational therapies utilize its proprietary mesenchymal stem cell secretome (MSC-S) platform. The Company’s product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biocfactors, such as growth factors, protease inhibitors, matrix proteins and neurotrophic factors that can potentially correct the impaired corneal healing, which is an underlying etiology of multiple severe ocular diseases; KPI-014 specific for inherited retinal degenerative diseases. KPI-012 is in clinical development for the treatment of persistent corneal epithelial defect (PCED), a rare disease of impaired corneal healing. The Company is also engaged in the development of KPI-012 for the treatment of Limbal Stem Cell Deficiency and other rare corneal diseases.

What is the price predicton of KALA Stock?

What is KALA BIO Inc (KALA)'s revenue for the last quarter?

KALA BIO Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

What is KALA BIO Inc (KALA)'s earnings per share (EPS) for the last quarter?

KALA BIO Inc. EPS for the last quarter amounts to -1.07 USD, decreased -44.56 % YoY.

What changes have occurred in the market's expectations for KALA BIO Inc (KALA)'s fundamentals?

How many employees does KALA BIO Inc (KALA). have?

KALA BIO Inc (KALA) has 38 emplpoyees as of January 09 2026.

What is KALA BIO Inc (KALA) market cap?

Today KALA has the market capitalization of 15.09M USD.